Human studySexual health · 1 Nov 2019
Bremelanotide improved sexual desire in two phase 3 trials
The RECONNECT studies evaluated this melanocortin agonist in premenopausal women with hypoactive sexual desire.
Bremelanotide, also known as PT-141, acts on melanocortin receptors in the central nervous system. The RECONNECT studies were two identical phase 3, randomised, placebo-controlled trials.
In both, bremelanotide improved sexual desire and reduced related distress versus placebo. The most frequent adverse events were nausea, flushing and headache, mostly mild or moderate.
In three points
- Two phase 3 human trials
- More sexual desire and less related distress
- Acts on melanocortin receptors in the brain
Original source: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
PubMed · Obstetrics & Gynecology
PubMed · Obstetrics & Gynecology
Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.